Metro-Minnesota Community Clinical Oncology Program

描述(由申请人提供)： 大都会-明尼苏达州社区临床肿瘤学计划(MMCCOP)代表了一个由九家医院组成的联盟，这些医院通过NCI资助的社区医院肿瘤学计划(CHOP)和运营的CCOP，开发了一种共同的癌症患者管理方法，并建立了识别、进入和跟踪患者治疗和癌症预防和控制方案的机制。该联盟拥有一个全社会范围的电脑化数据管理系统，能够收集未来的数据。该社区提供PPO、HMO和商业医疗计划，所有这些都代表了这九家联盟医院。这九家医院加在一起，平均每年新增9700名癌症分析患者。100名核心和即将到来的新研究人员代表了内科和放射肿瘤学、血液学、泌尿学、妇科肿瘤学、神经病学、耳鼻喉科、家庭实践、普通外科和专科外科医生，他们在癌症项目开发和当前项目结构和操作的方案开发方面进行了广泛的合作。在最近的NCI资助资助年度(6/03-5/04)，880名患者/参与者(192.3个治疗学分+299.6个癌症控制学分)累积到NCI批准的治疗和癌症预防和控制研究中。MMCCOP打算维持一个区域范围的社区和医院联盟，向社区提供癌症预防、控制和治疗方面的最新进展。将通过以下方式实现这一目标：将癌症治疗方案进一步扩展到已建立的外联社区；与医院、基金会、保险公司和综合服务网络合作，为参与临床试验提供资金和报销支持；增加初级保健医生的参与；提供专业知识、资源和庞大的人口基础，通过与NCI、CTSU、ECOG、GOG、MD Anderson、NSABP、RTOG、URCC和NCCTG的试点项目建立联系，开发、实施和评估临床癌症治疗和控制试验；改进和扩大目前的MMCCOP数据管理和通信系统，以增加研究人员参与权责发生、方案运作和研究基地活动的数量和水平；实施新的战略，改善少数群体和未得到充分服务的群体的机会和参与；提高专业和非专业社区对CCOP和癌症临床试验好处的认识。根据过去的经验、癌症控制和预防试验的可获得性、多个研究基地和成功的癌症控制实施模式，MMCCOP调查人员打算在第一年招募1,040名患者/参与者参加国家癌症研究所批准的癌症治疗和控制研究，目标是继续超过国家癌症研究所对这两类研究的要求。当时的评审员认为之前的MMCCOP应用程序“过于乐观”，但被超过了。这笔赠款的第一年的目标再次乐观，但考虑到该小组的专业知识、可用的方案、既定的系统以及医生和医院的大力支持，这一目标是现实的。

DESCRIPTION (provided by applicant): The Metro-Minnesota Community Clinical Oncology Program (MMCCOP) represents a consortium of nine hospitals which, through its NCI-funded Community Hospital Oncology Program ("CHOP") and operational CCOP, has developed a common approach to the management of cancer patients and has an established mechanism for identifying, entering and following patients on treatment and cancer prevention and control protocols. The consortium has a community-wide computerized data management system capable of prospective data collection. The community offers PPO's, HMOs and commercial healthcare programs, all of which are represented among these nine consortium hospitals. Together, the nine hospitals see an average of 9700 new analytic cancer patients per year. The 100 core and pending new investigators, representing medical and radiation oncology, hematology, urology, gynecologic oncology, neurology, ENT, family practice, general and specialty surgeons, have worked extensively together on cancer program development and protocol development of the current program structure and operation. During the most recent NCI-funded grant year (6/03-5/04), 880 patients/participants (192.3 treatment credits+ 299.6 cancer control credits) were accrued to NCI-approved treatment and cancer prevention and control studies. The MMCCOP intends to sustain a region wide community and hospital consortium, which provides the community with the most recent advances in cancer prevention, control and treatment. This will be accomplished through further expansion of the CCOP into established outreach communities; work with hospitals, foundations, insurers and Integrated Service Networks (ISNs) to develop funding and reimbursement support for participation in clinical trials; increased involvement of primary care physicians; providing the expertise, resources, and large population base to develop, implement and evaluate clinical cancer treatment and control trials through affiliation with the NCI, CTSU, ECOG, GOG, MD Anderson, NSABP, RTOG, URCC and pilot project with the NCCTG; improve and expand the current MMCCOP data management and communication system to increase the number and level of participation of the investigators in accrual, program operations and research base activities; implement new strategies to improve access and participation of minority and underserved groups; and increase the professional and lay community awareness of the CCOP and benefits of clinical cancer trials. Based upon past experience, the availability of cancer control and prevention trials, multiple research bases and successful cancer control implementation models, MMCCOP investigators intend to enroll 1040 (581.6 credits/413.5 new + 168.1 follow-up) patients/participants onto NCI-approved cancer treatment and control studies during the first year, with the goal of continually exceeding the NCI requirements for both types of studies. Prior MMCCOP applications were viewed by reviewers at that time as "overly optimistic", but were exceeded. The goal for the first year of this grant is again optimistic, but realistic given the expertise of the group, available protocols, the established systems and strong support of the physicians and hospitals.